CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Abidol hydrochlorideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug102 Abidol Hydrochloride combined with Interferon atomization Wiki 0.71
drug1706 Oseltamivir Wiki 0.29
drug1372 Lopinavir/ritonavir Wiki 0.22

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.08

There are 2 clinical trials

Clinical Trials


1 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.

NCT04254874 2019-nCoV Drug: Abidol hydrochloride Drug: Abidol Hydrochloride combined with Interferon atomization
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2> 300mmHg (1mmHg=0.133Kpa);

Measure: Rate of disease remission

Time: two weeks

Description: Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.

Measure: Time for lung recovery

Time: two weeks

Secondary Outcomes

Measure: Rate of no fever

Time: two weeks

Measure: Rate of respiratory symptom remission

Time: two weeks

Measure: Rate of lung imaging recovery

Time: two weeks

Measure: Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery

Time: two weeks

Measure: Rate of undetectable viral RNA

Time: two weeks

2 An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.

NCT04255017 2019-nCoV Drug: Abidol hydrochloride Drug: Oseltamivir Drug: Lopinavir/ritonavir
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2>300mmHg (1mmHg=0.133Kpa);

Measure: Rate of disease remission

Time: two weeks

Description: Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.

Measure: Time for lung recovery

Time: two weeks

Secondary Outcomes

Measure: Rate of no fever

Time: two weeks

Measure: Rate of respiratory symptom remission

Time: two weeks

Measure: Rate of lung imaging recovery

Time: two weeks

Measure: Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery

Time: two weeks

Measure: Rate of undetectable viral RNA

Time: two weeks


Related HPO nodes (Using clinical trials)